203 related articles for article (PubMed ID: 28126961)
1. miR-125b and miR-532-3p predict the efficiency of rituximab-mediated lymphodepletion in chronic lymphocytic leukemia patients. A French Innovative Leukemia Organization study.
Gagez AL; Duroux-Richard I; Leprêtre S; Orsini-Piocelle F; Letestu R; De Guibert S; Tuaillon E; Leblond V; Khalifa O; Gouilleux-Gruart V; Banos A; Tournilhac O; Dupuis J; Jorgensen C; Cartron G; Apparailly F
Haematologica; 2017 Apr; 102(4):746-754. PubMed ID: 28126961
[TBL] [Abstract][Full Text] [Related]
2. miRNA profile at diagnosis predicts treatment outcome in patients with B-chronic lymphocytic leukemia: A FILO study.
Duroux-Richard I; Gagez AL; Alaterre E; Letestu R; Khalifa O; Jorgensen C; Leprêtre S; Tchernonog E; Moreaux J; Cartron G; Apparailly F
Front Immunol; 2022; 13():983771. PubMed ID: 36325355
[TBL] [Abstract][Full Text] [Related]
3. Opposite Prognostic Significance of Cellular and Serum Circulating MicroRNA-150 in Patients with Chronic Lymphocytic Leukemia.
Stamatopoulos B; Van Damme M; Crompot E; Dessars B; Housni HE; Mineur P; Meuleman N; Bron D; Lagneaux L
Mol Med; 2015 Jan; 21(1):123-33. PubMed ID: 25584781
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia.
Ferrajoli A; Shanafelt TD; Ivan C; Shimizu M; Rabe KG; Nouraee N; Ikuo M; Ghosh AK; Lerner S; Rassenti LZ; Xiao L; Hu J; Reuben JM; Calin S; You MJ; Manning JT; Wierda WG; Estrov Z; O'Brien S; Kipps TJ; Keating MJ; Kay NE; Calin GA
Blood; 2013 Sep; 122(11):1891-9. PubMed ID: 23821659
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA-92a-3p overexpression in peripheral blood mononuclear cells is an independent predictor of prolonged overall survival of patients with chronic lymphocytic leukemia.
Papageorgiou SG; Diamantopoulos MA; Kontos CK; Bouchla A; Vasilatou D; Bazani E; Scorilas A; Pappa V
Leuk Lymphoma; 2019 Mar; 60(3):658-667. PubMed ID: 29911923
[TBL] [Abstract][Full Text] [Related]
6. Rituximab, cladribine, and cyclophosphamide (RCC) induction with rituximab maintenance in chronic lymphocytic leukemia: PALG - CLL4 (ML21283) trial.
Robak T; Błoński J; Skotnicki AB; Piotrowska M; Wróbel T; Rybka J; Kłoczko J; Bołkun Ł; Budziszewska BK; Walczak U; Uss A; Fidecka M; Smolewski P
Eur J Haematol; 2018 May; 100(5):465-474. PubMed ID: 29427355
[TBL] [Abstract][Full Text] [Related]
7. A phase I dose-ranging study of bendamustine and rituximab in chronic lymphocytic leukemia patients with comorbidities.
Danilov AV; Lewis LD; Lansigan F; Roudaia L; Findley DL; Jones SY; Highhouse B; Beaulieu BB; Brown JR
Br J Haematol; 2017 Sep; 178(5):820-823. PubMed ID: 27377970
[No Abstract] [Full Text] [Related]
8. IL-4 Up-Regulates MiR-21 and the MiRNAs Hosted in the CLCN5 Gene in Chronic Lymphocytic Leukemia.
Ruiz-Lafuente N; Alcaraz-García MJ; Sebastián-Ruiz S; García-Serna AM; Gómez-Espuch J; Moraleda JM; Minguela A; García-Alonso AM; Parrado A
PLoS One; 2015; 10(4):e0124936. PubMed ID: 25909590
[TBL] [Abstract][Full Text] [Related]
9. Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.
Seymour JF; Kipps TJ; Eichhorst B; Hillmen P; D'Rozario J; Assouline S; Owen C; Gerecitano J; Robak T; De la Serna J; Jaeger U; Cartron G; Montillo M; Humerickhouse R; Punnoose EA; Li Y; Boyer M; Humphrey K; Mobasher M; Kater AP
N Engl J Med; 2018 Mar; 378(12):1107-1120. PubMed ID: 29562156
[TBL] [Abstract][Full Text] [Related]
10. A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia.
Kipps TJ; Eradat H; Grosicki S; Catalano J; Cosolo W; Dyagil IS; Yalamanchili S; Chai A; Sahasranaman S; Punnoose E; Hurst D; Pylypenko H
Leuk Lymphoma; 2015; 56(10):2826-33. PubMed ID: 25797560
[TBL] [Abstract][Full Text] [Related]
11. Improved survival outcomes with the addition of rituximab to initial therapy for chronic lymphocytic leukemia: a comparative effectiveness analysis in the province of British Columbia, Canada.
Lee LJ; Toze CL; Huang SJT; Gillan TL; Connors JM; Sehn LH; Bruyere H; Leitch H; Ramadan KM; Gerrie AS
Leuk Lymphoma; 2018 Jun; 59(6):1356-1363. PubMed ID: 29032719
[TBL] [Abstract][Full Text] [Related]
12. Elevated miR-20b-5p expression in peripheral blood mononuclear cells: A novel, independent molecular biomarker of favorable prognosis in chronic lymphocytic leukemia.
Papageorgiou SG; Kontos CK; Tsiakanikas P; Stavroulaki G; Bouchla A; Vasilatou D; Bazani E; Lazarakou A; Scorilas A; Pappa V
Leuk Res; 2018 Jul; 70():1-7. PubMed ID: 29715621
[TBL] [Abstract][Full Text] [Related]
13. Relationship between venetoclax exposure, rituximab coadministration, and progression-free survival in patients with relapsed or refractory chronic lymphocytic leukemia: demonstration of synergy.
Freise KJ; Jones AK; Menon RM; Verdugo ME; Humerickhouse RA; Awni WM; Salem AH
Hematol Oncol; 2017 Dec; 35(4):679-684. PubMed ID: 27982454
[TBL] [Abstract][Full Text] [Related]
14. First-line therapy for chronic lymphocytic leukemia in patients older than 79 years is feasible and achieves good results: A FILO retrospective study.
Meunier G; Ysebaert L; Nguyen-Thi PL; Lepretre S; Quinquenel A; Dupuis J; Lemal R; Aurran T; Tomowiak C; Cymbalista F; Dilhuydy MS; Brion A; Morel P; Cazin B; Leblond V; Cartron G; Ré D; Béné MC; Michallet AS; Feugier P
Hematol Oncol; 2017 Dec; 35(4):671-678. PubMed ID: 27878835
[TBL] [Abstract][Full Text] [Related]
15. Rituximab in combination with chemotherapy for the treatment of chronic lymphocytic leukaemia in clinical practice.
Reiser M; Dörfel S; Hensel M; Hoesl M; Jordan WO; Koenigsmann M; Meyer D; Reichert D; Schwarzer A; Marquardt M; Kellershohn K; Jentsch-Ullrich K
Eur J Haematol; 2018 May; 100(5):455-464. PubMed ID: 29393986
[TBL] [Abstract][Full Text] [Related]
16. Role of
Rampazzo E; Bojnik E; Trentin L; Bonaldi L; Del Bianco P; Frezzato F; Visentin A; Facco M; Semenzato G; De Rossi A
Haematologica; 2017 Jul; 102(7):e253-e256. PubMed ID: 28385779
[No Abstract] [Full Text] [Related]
17. Efficacy and safety of front-line therapy with fludarabine-cyclophosphamide-rituximab regimen for chronic lymphocytic leukemia outside clinical trials: the Israeli CLL Study Group experience.
Herishanu Y; Goldschmidt N; Bairey O; Ruchlemer R; Fineman R; Rahimi-Levene N; Shvidel L; Tadmor T; Ariel A; Braester A; Shapiro M; Joffe E; Polliack A;
Haematologica; 2015 May; 100(5):662-9. PubMed ID: 25661442
[TBL] [Abstract][Full Text] [Related]
18. The addition of rituximab to fludarabine improves clinical outcome in untreated patients with ZAP-70-negative chronic lymphocytic leukemia.
Del Poeta G; Del Principe MI; Consalvo MA; Maurillo L; Buccisano F; Venditti A; Mazzone C; Bruno A; Gianní L; Capelli G; Lo Coco F; Cantonetti M; Gattei V; Amadori S
Cancer; 2005 Dec; 104(12):2743-52. PubMed ID: 16284990
[TBL] [Abstract][Full Text] [Related]
19. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.
Hallek M; Fischer K; Fingerle-Rowson G; Fink AM; Busch R; Mayer J; Hensel M; Hopfinger G; Hess G; von Grünhagen U; Bergmann M; Catalano J; Zinzani PL; Caligaris-Cappio F; Seymour JF; Berrebi A; Jäger U; Cazin B; Trneny M; Westermann A; Wendtner CM; Eichhorst BF; Staib P; Bühler A; Winkler D; Zenz T; Böttcher S; Ritgen M; Mendila M; Kneba M; Döhner H; Stilgenbauer S; ;
Lancet; 2010 Oct; 376(9747):1164-74. PubMed ID: 20888994
[TBL] [Abstract][Full Text] [Related]
20. RNA-Seq Identifies Circulating miR-125a-5p, miR-125b-5p, and miR-143-3p as Potential Biomarkers for Acute Ischemic Stroke.
Tiedt S; Prestel M; Malik R; Schieferdecker N; Duering M; Kautzky V; Stoycheva I; Böck J; Northoff BH; Klein M; Dorn F; Krohn K; Teupser D; Liesz A; Plesnila N; Holdt LM; Dichgans M
Circ Res; 2017 Sep; 121(8):970-980. PubMed ID: 28724745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
